(Q39941516)

15 September 2017

title

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer (English)

1 reference

15 September 2017

1 reference

1 reference

1 reference

2

1 reference

15 September 2017

6

1 reference

15 September 2017

J D Hurt

1

1 reference

15 September 2017

L G Seamon

3

1 reference

15 September 2017

J F Fowler

4

1 reference

15 September 2017

L J Copeland

5

1 reference

15 September 2017

E Eisenhauer

7

1 reference

15 September 2017

R Salani

8

1 reference

15 September 2017

D M O'Malley

9

1 reference

15 September 2017

language of work or name

English

0 references

publication date

4 October 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

115

1 reference

15 September 2017

issue

3

1 reference

15 September 2017

page(s)

396-400

1 reference

15 September 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Angiogenesis as a strategic target for ovarian cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

CA125 response: can it replace the traditional response criteria in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Peripheral neuropathy induced by microtubule-stabilizing agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

The anti-angiogenic basis of metronomic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.032

10.1016/J.YGYNO.2009.08.032

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference